RANI Stock Forecast & Price Target

Rani Therapeutics Hldgs is supported by a differentiated oral biologics platform that has already shown unusually strong human validation, including >150% relative bioavailability versus subcutaneous PG-102, no serious or capsule-attributed adverse events, and a 30-volunteer Phase 1a dataset that materially de-risks RaniPill HC. The outlook is further strengthened by multiple monetization paths beyond RT-114, as the Chugai collaboration offers up to five additional targets and up to $1.8B in milestones, while PegBio expands the opportunity to earlier-stage obesity and metabolic candidates with more meaningful downstream economics. Financially, the company appears adequately funded, ending June with $53.4M in cash, cash equivalents and marketable securities, EPS of $(0.04) versus FactSet’s $(0.05), and R&D of $5.0M, giving it runway into 2027 and supporting the next catalysts by YE26 and in 2027.

Rani Therapeutics Hldgs is viewed negatively because its oral biologics platform still lacks broad human validation, with much of the evidence coming from relatively small and/or short-duration studies and chronic, repeat-dose performance remaining less proven than single-dose delivery. The investment case also depends on highly uncertain execution, including a 45% probability of success for RT-114 in Obesity and a 25% probability of success for the hemophilia collaboration with Chugai, alongside clinical, regulatory, partnering, and financing risks. Even if development succeeds, capital constraints, pipeline reprioritizations, and reliance on generic or biosimilar APIs could limit scale, market share, and pricing power, while competition and FDA caution around the RaniPill add further pressure.